½ÃÀ庸°í¼­
»óǰÄÚµå
1744604

¼¼°èÀÇ À¯¹æ º´º¯ ±¹¼ÒÈ­ ½ÃÀå : À¯Çüº°, ±¹¼ÒÈ­ ±â¼úº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®, ¿¹Ãø(-2032³â)

Breast Lesion Localization Market Forecasts to 2032 - Global Analysis By Type, Localization Technique, Application, End User, and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é ¼¼°è À¯¹æ º´º¯ ±¹¼ÒÈ­ ½ÃÀåÀº 2025³â 3¾ï 530¸¸ ´Þ·¯, ¿¹Ãø ±â°£ µ¿¾È CAGRÀº 6.3%¸¦ ³ªÅ¸³»°í 2032³â¿¡´Â 4¾ï 6,820¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀÔ´Ï´Ù.

À¯¹æ º´º¯ ±¹¼ÒÈ­´Â ¼ö¼ú ÀýÁ¦ Àü¿¡ À¯¹æÀÇ ºñÁ¤»ó Á¶Á÷°ú Á¾¾çÀ» Á¤È®ÇÏ°Ô ½Äº°ÇÏ°í ¸¶Å·ÇÏ´Â µ¥ »ç¿ëµÇ´Â ÀÇ·á ÀýÂ÷ÀÔ´Ï´Ù. ¿ÍÀÌ¾î ±¹¼ÒÈ­, ¹æ»ç¼º ½Ãµå ±¹¼ÒÈ­, Àڱ⠸¶Ä¿¿Í °°Àº ±â¼úÀº ¿Ü°úÀǻ縦 Á¤È®ÇÑ º´º¯ ºÎÀ§·Î À̲ø¾î °Ç°­ÇÑ Á¶Á÷À» ¿ÂÁ¸Çϸ鼭 Á¤È®ÇÑ ÀýÁ¦¸¦ º¸ÀåÇÕ´Ï´Ù. ÀÌ °úÁ¤Àº À¯¹æ¾ÏÀÇ Áø´Ü°ú Ä¡·á¿¡ ¸Å¿ì Áß¿äÇÏ¸ç ¼ö¼ú ¼ºÀûÀ» Çâ»ó½ÃŰ°í ºÒÇÊ¿äÇÑ À¯¹æ Á¶Á÷ ÀýÁ¦¸¦ ÃÖ¼ÒÈ­ÇÕ´Ï´Ù.

¹Ì±¹¾ÏÇùȸ(ACS)¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â 2023³â¿¡ 28¸¸¸í ÀÌ»óÀÇ Ä§À±¼º À¯¹æ¾ÏÀÇ ½Å±Ô »ç·Ê°¡ ¹ß»ýÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖÀ¸¸ç, ¼ö¼úÀû °³ÀÔÀ» À̲ø±â À§ÇÑ Á¤È®ÇÑ º´º¯ ±¹ÀçÀÇ Áß¿äÇÑ Çʿ伺ÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù.

À¯¹æ¾Ï ÀÌȯÀ² »ó½Â

À¯¹æ¾ÏÀº ¿©ÀüÈ÷ ¿©¼ºµé »çÀÌ¿¡¼­ °¡Àå ¸¹ÀÌ Áø´ÜµÇ´Â ¾Ï Áß ÇϳªÀ̸ç, º´º¯ÀÇ Á¶±â ¹ß°ß°ú Á¤È®ÇÑ ±¹¼ÒÈ­¿¡ ´ëÇÑ ¼ö¿ä´Â ±Þ¼ÓÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áõ·ÊÀÇ ±ÞÁõÀº ÀǽÄÀÇ Çâ»ó°ú °ËÁø ÇÁ·Î±×·¥ÀÇ È®´ë·Î À̾îÁ® Áø´Ü Á¤¹Ðµµ¿Í Ä¡·á ¼ºÀûÀ» Çâ»ó½ÃŰ´Â °í±Þ ±¹¼ÒÈ­ ±â¼úÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ À̹Ì¡°ú »ý°Ë¹ýÀÇ ±â¼úÀû Áøº¸´Â Àû½Ã¿¡ È¿°úÀûÀÎ °³ÀÔÀ» º¸ÀåÇϰí ÀÌ ½ÃÀå È®´ë¸¦ Áö¿øÇϰí ÀÖ½À´Ï´Ù.

Á¦ÇÑµÈ »óȯ Á¤Ã¥

¾ö°ÝÇÑ ÁöºÒ ±ÔÁ¦¿Í °í±Þ ±¹¼ÒÈ­ ±â¼ú¿¡ ´ëÇÑ Àû¿ë ¹üÀ§ÀÇ Á¦ÇÑÀº Çõ½ÅÀûÀÎ ±â¼úÀÇ º¸±ÞÀ» ¹æÇØÇÕ´Ï´Ù. »Ó¸¸ ¾Æ´Ï¶ó º¹ÀâÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ ÇÁ·Î¼¼½º¿Í ÅëÀÏµÈ »óȯ ƲÀÇ ºÎÁ·Àº ½ÃÀå ÁøÀÔÀ» ´ÊÃß°í »õ·Î¿î ±¹¼ÒÈ­ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÅõÀÚ¸¦ ¾ïÁ¦ÇÏ¸ç ±Ã±ØÀûÀ¸·Î´Â ȯÀÚÀÇ ÃÖ÷´Ü ÀÇ·á Á¢±Ù¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù.

AI¿Í µðÁöÅÐ °Ç°­ÀÇ ÅëÇÕ

AI¸¦ Ȱ¿ëÇÑ ¿µ»ó Áø´Ü ¹× µ¥ÀÌÅÍ ºÐ¼®Àº º´º¯ÀÇ °ËÃâ, ºÐ·ù, ¼ö¼ú °èȹÀÇ Á¤È®¼ºÀ» ³ô¿© ȯÀÚÀÇ °á°ú¿Í ¿öÅ©Ç÷οìÀÇ È¿À² °³¼±À¸·Î À̾îÁý´Ï´Ù. ÀÇ·á Á¦°øÀÚ°¡ ÀÌ·¯ÇÑ Ã·´Ü±â¼úÀ» Á¡Á¡ äÅÃÇÔ¿¡ µû¶ó ±â¼ú Çõ½Å, Áø´Ü Á¤È®µµ Çâ»ó, º¸´Ù °³º°È­µÈ ȯÀÚ Á᫐ ÄɾîÀÇ °¡´É¼ºÀ¸·Î ½ÃÀåÀº °¡¼ÓÀûÀ¸·Î ¼ºÀåÇϴ ż¼°¡ µÇ°í ÀÖ½À´Ï´Ù.

¹æ»ç¼± ³ëÃâ¿¡ ´ëÇÑ ¿ì·Á

¸¹Àº ±¹¼ÒÈ­ ±â¼ú, ƯÈ÷ À¯¹æ Á¶¿µ¼ú ¹× ¹æ»ç¼º µ¿À§ ¿ø¼Ò ±â¹Ý ¹æ¹ýÀº ȯÀÚ¿¡°Ô Àü¸® ¹æ»ç¼±À» Á¶»çÇϱ⠶§¹®¿¡ ȯÀÚ¿Í °Ç°­ °ü¸® Á¦°ø¾÷ü ¸ðµÎ¿¡°Ô ¾ÈÀü¼º¿¡ ´ëÇÑ ¿ì·Á°¡ ¹ß»ýÇÕ´Ï´Ù. ¶ÇÇÑ, ƯÁ¤ ±â¼úÀÇ Ã¤¿ëÀ» ¸Á¼³ÀÌ°Ô µË´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã¿Í ¾ÈÀü °¡À̵å¶óÀÎÀÇ ÁøÈ­´Â ¹æ»ç¼± ±â¹Ý ±¹¼ÒÈ­ÀÇ »ç¿ëÀ» ´õ¿í Á¦ÇÑÇÏ°í ¹æ»ç¼±À» »ç¿ëÇÏÁö ¾Ê´Â ´ëü ±â¼ú·ÎÀÇ ½ÃÇÁÆ®¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ :

COVID-19ÀÇ À¯ÇàÀº À¯¹æ º´º¯ ±¹¼ÒÈ­ ½ÃÀåÀ» Å©°Ô È¥¶õ½ÃÄ×Áö¸¸, ±× ÁÖ¿ä ¿øÀÎÀº ¼±ÅÃÀû ¼ö¼úÀÇ ¿¬±â¿Í °ËÁø °Ç¼öÀÇ °¨¼Ò¿´½À´Ï´Ù. ÀÌ·Î ÀÎÇØ Áø´Ü Áö¿¬, ³»¿ø½Ã Á¾¾ç Å©±â Áõ´ë, ±ÔÁ¦ ¿ÏÈ­ ÈÄ ÀϽÃÀûÀÎ »ç·Ê°¡ ³²¾ÆÀÖ°Ô µÇ¾ú½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È ¿ÍÀÌ¾î ±¹¼ÒÈ­ ºÎ¹®ÀÌ ÃÖ´ë°¡ µÉ Àü¸Á

¿¹Ãø ±â°£ µ¿¾È °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â °ÍÀº ¿ÍÀÌ¾î ±¹¼ÒÈ­ ºÎ¹®ÀÔ´Ï´Ù. ´ëºÎºÐÀÇ ¿Ü°ú ÆÀ¿¡°Ô Ä£¼÷ÇÏ°í ½Å·ÚÇÒ ¼öÀÖ´Â °£´ÜÇÑ Á¢±Ù¹ýÀ» Á¦°øÇÕ´Ï´Ù. »õ·Î¿î ±â¼úÀÇ ÃâÇö¿¡µµ ºÒ±¸Çϰí, ¿ÍÀÌ¾î ±¹¼ÒÈ­ ±â¼úÀÇ °£Æí¼º, »ç¿ë ÆíÀǼº, È®¸³ µÈ »óȯÀ¸·Î ¼¼°è ÀÇ·á Á¦°ø¾÷üµé »çÀÌ¿¡¼­ °è¼Ó ¼±È£µÇ°í ÀÖ½À´Ï´Ù.

¿¹Ãø±â°£ µ¿¾È ¿Ü·¡¼ö¼ú¼¾ÅÍ ºÐ¾ßÀÇ CAGRÀÌ °¡Àå ³ô¾ÆÁú Àü¸Á

¿¹Ãø ±â°£ µ¿¾È ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) ºÎ¹®ÀÌ °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ´Â °ÍÀº ³·Àº ħ½À À¯¹æ ¼ö¼úÀÇ ¿Ü·¡·ÎÀÇ À̵¿ÀÌ ÁøÇàµÇ¾î ȯÀÚ°¡ ȸº¹ ½Ã°£ ´ÜÃà°ú ºñ¿ë Àý°¨ÀÇ ÇýÅÃÀ» ¹Þ±â ¶§¹®ÀÔ´Ï´Ù. ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ´Â È¿À²ÀûÀ̰í ȯÀÚ Ä£È­ÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÷´Ü ±¹¼ÒÈ­ ±â¼úÀ» Á¡Á¡ ´õ ¸¹ÀÌ °®Ãß°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º´¿øÀÇ ¿¹»êÀÌ ÇÑÁ¤µÇ¾î ÀÖ¾î, ¼ö¼ú½ÇÀÇ ÀÌ¿ëÀ²À» ÃÖÀûÈ­ÇÏ´Â °Í¿¡ ÁßÁ¡À» µÎ°í ÀÖ´Â °Íµµ, ÀÌ·¯ÇÑ ¼¾ÅÍ¿¡¼­ÀÇ À¯¹æ º´º¯ ±¹¼ÒÈ­ ¼ö¹ýÀÇ Ã¤ÅÃÀ» ÇÑÃþ ´õ ¹Ð¾îÁÖ°í ÀÖ½À´Ï´Ù.

ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª :

¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¹Ì±¹Àº ±¤¹üÀ§ÇÑ ½É»ç ÇÁ·Î±×·¥, À¯¸®ÇÑ È¯±Þ Á¤Ã¥, ±×¸®°í ¿¬±¸ °³¹ß¿¡ ´ëÇÑ »ó´çÇÑ ÅõÀڷκÎÅÍ ÇýÅÃÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ À¯¹æ¾Ï¿¡ ´ëÇÑ ÀǽÄÀÇ °íÁ¶¿Í ÀÌȯÀ²ÀÇ »ó½Â¿¡ ÀÇÇØ Á¤È®ÇÑ ±¹¼ÒÈ­ ¼ö¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓµÇ°í ÀÖ¾î ºÏ¹Ì ½ÃÀåÀÇ ¿ìÀ§¼ºÀÌ °­ÇØÁö°í ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª :

¿¹Ãø ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.¿¡¼­´Â À¯¹æ¾Ï ÀÌȯÀ²ÀÌ ±ÞÁõÇϰí ÀÖ¾î, °í±Þ ±¹¼ÒÈ­ ±â¼úÀÇ Ã¤ÅÃÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¤ºÎÀÇ ´ëó, ÀÇ·á Åõ¾î¸®Áò Áõ°¡, ÇコÄɾÀÇ ¾×¼¼½ºÀÇ °³¼±¿¡ ÁÖ·ÂÇÏ´Â °ÍÀÌ, ½ÃÀåÀÇ °ßÁ¶ÇÑ È®´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

¹«·á ÁÖ¹®À» ¹Þ¾Æ¼­ ¸¸µå´Â ¼­ºñ½º :

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½ ¹«·á ¸ÂÃã¼³Á¤ ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀû ÇÁ·ÎÆÄÀϸµ(3°³»ç±îÁö)
    • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®(3°³»ç±îÁö)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ ÀÀÇÑ ÁÖ¿ä±¹ ½ÃÀå ÃßÁ¤, ¿¹Ãø ¹× CAGR(ÁÖ : Ÿ´ç¼º È®Àο¡ µû¸§)
  • °æÀï º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¸®Àû Á¸Àç, Àü·«Àû Á¦ÈÞ¿¡ ±â¹ÝÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç Á¢±Ù
  • Á¶»ç ÀÚ·á
    • 1Â÷ Á¶»ç ÀÚ·á
    • 2Â÷ Á¶»ç Á¤º¸¿ø
    • ÀüÁ¦Á¶°Ç

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • ¿ëµµ ºÐ¼®
  • ÃÖÁ¾ »ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • COVID-19ÀÇ ¿µÇâ

Á¦4Àå Porter's Five Forces ºÐ¼®

  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷°£ °æÀï °ü°è

Á¦5Àå ¼¼°èÀÇ À¯¹æ º´º¯ ±¹¼ÒÈ­ ½ÃÀå : À¯Çüº°

  • ¿ÍÀ̾îÀÇ À§Ä¡ ƯÁ¤
  • ¹æ»ç¼º µ¿À§ ¿ø¼ÒÀÇ ±¹Àç
    • ¶óµð¿À °¡À̵å ÇÏ ÀáÀ缺 º´º¯ À§Ä¡ ƯÁ¤(ROLL)
    • ¹æ»ç¼º Á¾ÀÚÀÇ À§Ä¡ ƯÁ¤(RSL)
  • Àڱ⠱¹Àç
  • ÀüÀÚ±âÀû ±¹Àç
  • ±âŸ À¯Çü

Á¦6Àå ¼¼°èÀÇ À¯¹æ º´º¯ ±¹¼ÒÈ­ ½ÃÀå : ±¹¼ÒÈ­ ±â¼úº°

  • ÃÊÀ½ÆÄ °¡ÀÌµå ¾Æ·¡ ±¹¼ÒÈ­
  • MRI À¯µµ ±¹¼ÒÈ­
  • Á¤À§ À¯µµ¹ý ±¹¼ÒÈ­
  • ±âŸ ±â¼ú

Á¦7Àå ¼¼°èÀÇ À¯¹æ º´º¯ ±¹¼ÒÈ­ ½ÃÀå : ¿ëµµº°

  • Á¾¾çÀÇ Æ¯Á¤
  • ¼¾Æ¼³Ú ¸²ÇÁÀý °ËÃâ
  • »ý°Ë ¾È³»
  • ±âŸ ¿ëµµ

Á¦8Àå ¼¼°èÀÇ À¯¹æ º´º¯ ±¹¼ÒÈ­ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • º´¿ø
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • Á¾¾çÇРŬ¸®´Ð
  • Áø´Ü¼¾ÅÍ
  • Çмú¿¬±¸±â°ü

Á¦9Àå ¼¼°èÀÇ À¯¹æ º´º¯ ±¹¼ÒÈ­ ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ÁÖ¿ä ¹ßÀü

  • °è¾à, ÆÄÆ®³Ê½Ê, Çù¾÷, ÇÕÀÛÅõÀÚ
  • Àμö¿Í ÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀϸµ

  • Hologic, Inc.
  • Becton, Dickinson and Company
  • Merit Medical Systems, Inc.
  • Cianna Medical, Inc.
  • Cook Medical
  • Endomagnetics Ltd
  • Somatex Medical Technologies GmbH
  • Argon Medical Devices, Inc.
  • STERILAB Srl
  • Leica Biosystems Nussloch GmbH
  • GE Healthcare
  • Koninklijke Philips NV
  • Ambu A/S
  • Medline Industries Inc.
  • SurgicEye GmbH
  • Intra-Medical Imaging LLC
  • IsoAid, LLC
  • Mammotome
SHW 25.06.19

According to Stratistics MRC, the Global Breast Lesion Localization Market is accounted for $305.3 million in 2025 and is expected to reach $468.2 million by 2032 growing at a CAGR of 6.3% during the forecast period. Breast lesion localization is a medical procedure used to precisely identify and mark abnormal tissue or tumors within the breast before surgical removal. Techniques such as wire localization, radioactive seed localization, or magnetic markers guide surgeons to the exact lesion site, ensuring accurate excision while preserving healthy tissue. This process is crucial in breast cancer diagnosis and treatment, improving surgical outcomes and minimizing the removal of unnecessary breast tissue.

According to the American Cancer Society (ACS), over 280,000 new cases of invasive breast cancer were expected in the US in 2023, highlighting the critical need for accurate lesion localization to guide surgical interventions.

Market Dynamics:

Driver:

Rising incidence of breast cancer

Breast cancer remains one of the most commonly diagnosed cancers among women, and the demand for early detection and precise localization of lesions is growing rapidly. This surge in cases has led to heightened awareness and expanded screening programs, encouraging the adoption of advanced localization techniques to improve diagnostic accuracy and treatment outcomes. Furthermore, technological advancements in imaging and biopsy methods are supporting this market expansion, ensuring timely and effective interventions.

Restraint:

Limited reimbursement policies

Stringent payment regulations and restricted coverage for advanced localization procedures hinder the widespread adoption of innovative technologies. This challenge is particularly acute in developing countries and resource-constrained healthcare settings, where the high initial cost of modern devices further limits access. Additionally, complex regulatory approval processes and the lack of uniform reimbursement frameworks can delay market entry and discourage investment in new localization solutions, ultimately impacting patient access to cutting-edge care.

Opportunity:

Integration of AI and digital health

AI-driven imaging and data analytics are enhancing the precision of lesion detection, classification, and surgical planning, leading to improved patient outcomes and workflow efficiency. Moreover, digital health platforms facilitate remote consultations and real-time collaboration among multidisciplinary teams. As healthcare providers increasingly adopt these advanced technologies, the market is poised for accelerated growth, driven by innovation, improved diagnostic accuracy, and the potential for more personalized, patient-centric care.

Threat:

Concerns about radiation exposure

Many localization techniques, especially those relying on mammography or radioisotope-based methods, expose patients to ionizing radiation, raising safety concerns among both patients and healthcare providers. This apprehension can lead to hesitancy in adopting certain technologies, particularly for repeated procedures or in populations sensitive to radiation risks. Moreover, regulatory scrutiny and evolving safety guidelines may further restrict the use of radiation-based localization, prompting a shift toward alternative, non-radiative techniques.

Covid-19 Impact:

The Covid-19 pandemic significantly disrupted the breast lesion localization market, primarily due to the postponement of elective procedures and reduced screening volumes. Many breast imaging facilities experienced an 80%-100% decline in patient volume, with screening mammography delayed in most practices. This led to delayed diagnoses, increased tumor sizes at presentation, and a temporary backlog of cases once restrictions eased. Furthermore, patient hesitancy to visit healthcare facilities and logistical challenges in resuming routine care contributed to a prolonged recovery in breast imaging and localization services.

The wire localization segment is expected to be the largest during the forecast period

The wire localization segment is expected to account for the largest market share during the forecast period. This dominance is attributed to its longstanding clinical acceptance, proven efficacy, and cost-effectiveness. Wire localization is widely used for guiding surgeons to non-palpable breast lesions, offering a reliable and straightforward approach that is familiar to most surgical teams. Despite the emergence of newer technologies, the simplicity, accessibility, and established reimbursement for wire localization procedures ensure its continued preference among healthcare providers globally.

The ambulatory surgical centers segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the ambulatory surgical centers segment is predicted to witness the highest growth rate driven by the increasing shift of minimally invasive breast procedures to outpatient settings, where patients benefit from shorter recovery times and reduced costs. Ambulatory surgical centers are increasingly equipped with advanced localization technologies, catering to the growing demand for efficient, patient-friendly care. Additionally, limited hospital budgets and a focus on optimizing operating room utilization further propel the adoption of breast lesion localization procedures in these centers.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by robust healthcare infrastructure, high adoption of advanced imaging and localization technologies, and the presence of major industry players. The United States, in particular, benefits from extensive screening programs, favorable reimbursement policies, and significant investments in research and development. Moreover, heightened awareness and the rising incidence of breast cancer ensure sustained demand for precise localization methods, reinforcing North America's dominant market position.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. The region's rapid growth is fueled by expanding healthcare infrastructure, rising disposable incomes, and increasing awareness of early breast cancer detection. Countries such as China, India, and Japan are experiencing a surge in breast cancer incidence, prompting greater adoption of advanced localization technologies. Additionally, government initiatives, growing medical tourism and a focus on improving healthcare accessibility are driving robust market expansion.

Key players in the market

Some of the key players in Breast Lesion Localization Market include Hologic, Inc., Becton, Dickinson and Company, Merit Medical Systems, Inc., Cianna Medical, Inc., Cook Medical, Endomagnetics Ltd, Somatex Medical Technologies GmbH, Argon Medical Devices, Inc., STERILAB S.r.l., Leica Biosystems Nussloch GmbH, GE Healthcare, Koninklijke Philips N.V., Ambu A/S, Medline Industries Inc., SurgicEye GmbH, Intra-Medical Imaging LLC, IsoAid, LLC and Mammotome.

Key Developments:

In April 2024, the Radiological Society of North America (RSNA) and GE HealthCare announced their collaboration to provide mammography technology, training and educational tools to radiologists at Muhimbili National Hospital (MNH), part of the Muhimbili University of Health and Sciences (MUHAS), in Tanzania to improve access to screening and help clinicians lower the country's breast cancer mortality rate.

In November 2023, GE HealthCare announced the release of a new, all-in-one platform of artificial intelligence (AI) apps to support clinicians with breast cancer detection and improved workflow productivity called MyBreastAI Suite*. With this initial release, MyBreastAI Suite integrates three AI applications from iCAD including ProFound AI for DBT, SecondLook for 2D Mammography and PowerLook Density Assessment to help support early detection and improve patient outcomes, as well as help radiology departments improve operational productivity.

Types Covered:

  • Wire Localization
  • Radioisotope Localization
  • Magnetic Localization
  • Electromagnetic Localization
  • Other Types

Localization Techniques Covered:

  • Ultrasound-guided Localization
  • MRI-guided Localization
  • Stereotactic-guided Localization
  • Other Techniques

Applications Covered:

  • Tumor Identification
  • Sentinel Lymph Node Detection
  • Biopsy Guidance
  • Other Applications

End Users Covered:

  • Hospitals
  • Ambulatory Surgical Centers
  • Oncology Clinics
  • Diagnostic Centers
  • Academic & Research Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Breast Lesion Localization Market, By Type

  • 5.1 Introduction
  • 5.2 Wire Localization
  • 5.3 Radioisotope Localization
    • 5.3.1 Radio-Guided Occult Lesion Localization (ROLL)
    • 5.3.2 Radioactive Seed Localization (RSL)
  • 5.4 Magnetic Localization
  • 5.5 Electromagnetic Localization
  • 5.6 Other Types

6 Global Breast Lesion Localization Market, By Localization Technique

  • 6.1 Introduction
  • 6.2 Ultrasound-guided Localization
  • 6.3 MRI-guided Localization
  • 6.4 Stereotactic-guided Localization
  • 6.5 Other Techniques

7 Global Breast Lesion Localization Market, By Application

  • 7.1 Introduction
  • 7.2 Tumor Identification
  • 7.3 Sentinel Lymph Node Detection
  • 7.4 Biopsy Guidance
  • 7.5 Other Applications

8 Global Breast Lesion Localization Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Ambulatory Surgical Centers
  • 8.4 Oncology Clinics
  • 8.5 Diagnostic Centers
  • 8.6 Academic & Research Institutes

9 Global Breast Lesion Localization Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Hologic, Inc.
  • 11.2 Becton, Dickinson and Company
  • 11.3 Merit Medical Systems, Inc.
  • 11.4 Cianna Medical, Inc.
  • 11.5 Cook Medical
  • 11.6 Endomagnetics Ltd
  • 11.7 Somatex Medical Technologies GmbH
  • 11.8 Argon Medical Devices, Inc.
  • 11.9 STERILAB S.r.l.
  • 11.10 Leica Biosystems Nussloch GmbH
  • 11.11 GE Healthcare
  • 11.12 Koninklijke Philips N.V.
  • 11.13 Ambu A/S
  • 11.14 Medline Industries Inc.
  • 11.15 SurgicEye GmbH
  • 11.16 Intra-Medical Imaging LLC
  • 11.17 IsoAid, LLC
  • 11.18 Mammotome
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦